Drug
Sys6010
Sys6010: highest development phase Phase 3, developed by CSPC Megalith Biopharmaceutical Co.,Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| SYS6010 NCT07672223 | Phase 3 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Sys6010 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.